Jerini AG Reaches Agreement to Sell JPT Peptide Technologies GmbH to TheraCode GmbH

07-May-2009 - Germany

Jerini AG has reached an agreement to sell its wholly-owned subsidiary, JPT Peptide Technologies GmbH to TheraCode GmbH, Mainz, a wholly-owned subsidiary of BioNTech AG, Mainz. Under the terms of the agreement, TheraCode GmbH will pay Jerini AG a purchase price of approximately € 5 million in cash. The sale of JPT Peptide Technologies GmbH to TheraCode GmbH is a further achievement in the implementation of Jerini AG's strategic decision published on October 10, 2008 to divest all non-strategic businesses and to focus on the core business Firazyr.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances